Abstract
The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.
Original language | English (US) |
---|---|
Pages (from-to) | 1062-1067 |
Number of pages | 6 |
Journal | Cancer Gene Therapy |
Volume | 9 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2002 |
Keywords
- Cancer
- Experimental therapeutics
- Oncolytic
- Virotherapy
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Cancer Research